Overview
Atrial Fibrillation
Cancer Associated Thrombosis
The Promise of Factor XI
Abelacimab: A Novel Anticoagulant
Clinical Development Program
Our Mission
Our Team
Milestones & Achievements
Patient Advocacy
Healthcare Professionals
Healio
https://www.healio.com/news/cardiology/20231112/factor-xi-inhibitor-for-af-drastically-reduces-bleeding-vs-rivaroxaban-in-phase-2-trial
